AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
A Look at Spark’s Potential Revenue Contribution to Roche Holdings
Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
GSK highlighted the prioritization of research and development programs, business development, and new product launches as its key growth drivers in 2018.
What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?
In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as its key drivers.
What Are the Key Growth Drivers for Pfizer in Fiscal 2019?
According to Pfizer’s fourth-quarter earnings conference call, Ibrance has managed to report global revenues of $4.1 billion in fiscal 2018.
Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.
AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.
What Are Abbott Laboratories’ Key Growth Drivers in 2019?
On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.
Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) highlighted increasing biosimilar and generic competition, pricing pressure, and the strengthening of the US dollar as key challenges for the company in fiscal 2019.
Johnson & Johnson to Focus on Increasing Research and Development
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) has projected its effective tax rate for fiscal 2019 to fall in the range of 17% to 18%.
Pfizer’s Expenses Are Expected to Rise in Fiscal 2019
Pfizer expects its adjusted SI&A expenses to fall by $13.5 billion–$14.5 billion in fiscal 2019—a decline of ~$200 million YoY at the midpoint.
Why China’s Iron Ore Demand Could Soon Weaken
As China consumes more than 70% of seaborne-traded iron ore, it’s imperative for iron ore investors to track the country’s demand and outlook.
FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.
Will Walgreens’s Strategic Initiatives Boost Its Sales?
Walgreens Boots Alliance’s (WBA) sales rose 9.9% to $33.8 billion in the first quarter of fiscal 2019 (which ended on November 30, 2018).
What Do Analysts Recommend for Abbott Laboratories in January?
The 12-month consensus analyst recommendation for Abbott Laboratories on January 18 is a “buy.”
Can Stanley Black & Decker’s Q4 Earnings Beat the Estimates?
Stanley Black & Decker (SWK) is expected to post an adjusted EPS of $2.1 in the fourth quarter—a decrease of ~4.7% YoY (year-over-year).
Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion.
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast total 2018 revenue in the range of $18.6 billion–$19.0 billion.
Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years
Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.
Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years
According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Pfizer and GlaxoSmithKline Form a Joint Venture
On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.
How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.
How IBM Is Investing in AI Solutions
AI is the buzzword these days, and the market has huge growth potential.
Ajovy Is a New Growth Driver for Teva Pharmaceutical
On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
A Look at Abraxane’s Revenue Growth Trajectory in 2018
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.
Inflammation and Immunology: Celgene’s Diversified Research Pipeline
Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.
Merck’s Stock Price Has Increased ~34% in 2018
On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.
Analyzing 22nd Century Group’s Year-to-Date Performance
Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.
How Nektar Performed in the Third Quarter
Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.
How Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.
Gilead Sciences: Analysts’ Recommendations
In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
A Performance Overview of Merck’s Hospital Acute Care Business
Merck & Co.’s (MRK) Bridion generated revenues of $217 million in the third quarter, which reflected a ~17% YoY growth.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
How JNJ’s Invega Sustenna and Risperdal Consta Performed
Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.
A Look into Johnson & Johnson’s Diabetes Care Business
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
NASH Opportunity Driving Growth for Viking Therapeutics in 2018
On October 8, Viking Therapeutics announced positive data from its in vivo study evaluating VK2809 in glycogen storage disease type la (or GDS la) indication.
What Analysts Recommend for Stryker Stock
Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.
What Are Pfizer’s Revenue Drivers?
Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.
A Look at the Performance of Novartis’s Alcon
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.
An Overview of Johnson & Johnson’s Neuroscience Segment
Of the 20 analysts tracking Johnson & Johnson stock in October, four recommended a “strong buy” while six analysts recommended a “buy.”
ABT Expands in Europe with Freestyle Libre 2 Approval
On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.
A Look at Elanco, Eli Lilly’s Animal Health Business
Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
What Devon Energy’s Technical Indicators Tell Us
Devon Energy (DVN) continues to trade below its short-term (50-day) moving average.
What ViewRay’s Valuation Trend Indicates
In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.